Skip to content
PulseMS
Research & community

MS research, together.

MS research in plain English. Perspectives from people who understand.

Research evidence filters

Filters apply to reviewed research. Unknown dates and unassessed posts are excluded when a corresponding filter is active.

Reset filters
Topics & sourcesFiltered
Research and community updates, newest first.#DMTsClear filters
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedSubjects not reportedSystematic reviewPeer review unconfirmed

Stem Cell Therapies for Demyelinating Diseases: Systematic Review

A systematic review found that autologous hematopoietic stem cell transplantation (AHSCT) is the most supported therapy for highly active relapsing MS, primarily aiding through immune system reconstitution. In contrast, mesenchymal stromal cell (MSC) methods remain investigational due to unresolved efficacy and safety issues, while avenues such as MSC-derived extracellular vesicles and iPSC-derived products are still in preclinical stages.

What this does not proveThe review does not provide specific clinical trial results, and numerous factors, such as product heterogeneity and safety concerns, limit the translation of these therapies into clinical practice.
View abstract on PubMedPMID 42789490AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studySystematic reviewPeer-reviewed

Human studies on α7-nAChR activation in MS

A systematic review indicates that activation of the α7-nAChR may lead to reduced inflammation and support nerve resilience in the central nervous system (CNS).

What this does not proveHowever, there are challenges to translating these findings into clinical practice, such as receptor desensitization and the absence of validated biomarkers.
#Immunomodulation#Neuroprotection#DMTsRelevant to Neurologist, Immunologist
View abstract on PubMedPMID 42790772AI summary of a published abstract. Not medical advice.